Antidepressant-like effect of the mGluR5 antagonist MTEP in an astroglial degeneration model of depression

Behavioural Brain Research

Volumn 273, Issue , 2014, Pages 23-33

  Domin, Helena ^a   Szewczyk, Bernadeta ^a   Woźniak, Monika ^a   Wawrzak Wleciał, Anika ^a   Śmiałowska, Maria ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Depression; Gliotoxin; L AAA; MGluR5 antagonist; MTEP

Indexed keywords

3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; AMINOADIPIC ACID; GLIAL FIBRILLARY ACIDIC PROTEIN; IMIPRAMINE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; 2 AMINOADIPIC ACID; 3-((2-METHYL-1,3-THIAZOL-4-YL)ETHYNYL)PYRIDINE; ANTIDEPRESSANT AGENT; GRM5 PROTEIN, RAT; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; ASTROCYTE; BRAIN LEVEL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; FORCED SWIM TEST; GLUTAMATERGIC TRANSMISSION; IMMOBILITY; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RAT MODEL; STAINING; STEREOLOGY; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; SPRAGUE DAWLEY RAT;

2-AMINOADIPIC ACID; ANIMALS; ANTIDEPRESSIVE AGENTS; ASTROCYTES; DEPRESSION; DISEASE MODELS, ANIMAL; MALE; MOTOR ACTIVITY; PREFRONTAL CORTEX; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, METABOTROPIC GLUTAMATE 5; THIAZOLES;

EID: 84905225358     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.07.019     Document Type: Article

References (115)

1. Ongür D., Drevets W.C., Price J.L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998, 95:13290-13295.
2. Cotter D., Mackay D., Landau S., Kerwin R., Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001, 58:545-553.
3. Sanacora G., Banasr M. From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol Psychiatry 2013, 73:1172-1179.
4. Rajkowska G., Stockmeier C.A. Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr Drug Targets 2013, 14:1225-1236.
5. Rajkowska G., Miguel-Hidalgo J.J. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007, 6:219-233.
6. Banasr M., Duman R.S. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry 2008, 64:863-870.
7. Volterra A., Meldolesi J. Astrocytes, from brain glue to communication elements: the revolution continues. Nat Rev Neurosci 2005, 6:626-640.
8. Largo C., Cuevas P., Somjen G.G., Martín del Río R., Herreras O. The effect of depressing glial function in rat brain in situ on ion homeostasis, synaptic transmission, and neuron survival. J Neurosci 1996, 16:1219-1229.
9. Bergles D.E., Jahr C.E. Synaptic activation of glutamate transporters in hippocampal astrocytes. Neuron 1997, 19:1297-1308.
10. Mennerick S., Zorumski C.F. Glial contributions to excitatory neurotransmission in cultured hippocampal cells. Nature 1994, 368:59-62.
11. Araque A., Carmignoto G., Haydon P.G. Dynamic signaling between astrocytes and neurons. Annu Rev Physiol 2001, 63:795-813.
12. Sofroniew M.V., Vinters H.V. Astrocytes: biology and pathology. Acta Neuropathol 2010, 119:7-35.
13. Araque A., Parpura V., Sanzgiri R.P., Haydon P.G. Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci 1999, 22:208-215.
14. Perea G., Navarrete M., Araque A. Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci 2009, 32:421-431.
15. Haydon P.G., Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev 2006, 86:1009-1031.
16. Anderson C.M., Swanson R.A. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia 2000, 32:1-14.
17. Wierońska J.M., Pilc A. Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. Neurochem Int 2009, 55:85-97.
18. Smiałowska M., Szewczyk B., Woźniak M., Wawrzak-Wleciał A., Domin H. Glial degeneration as a model of depression. Pharmacol Rep 2013, 65:1572-1579.
19. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009, 61:105-123.
20. Hashimoto K. The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1558-1568.
21. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007, 62:1310-1316.
22. Levine J., Panchalingam K., Rapoport A., Gershon S., McClure R.J., Pettegrew J.W. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 2000, 47:586-593.
23. Altamura C.A., Mauri M.C., Ferrara A., Moro A.R., D'Andrea G., Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 1993, 150:1731-1733.
24. Mauri M.C., Ferrara A., Boscati L., Bravin S., Zamberlan F., Alecci M., et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 1998, 37:124-129.
25. Mitani H., Shirayama Y., Yamada T., Maeda K., Ashby C.R., Kawahara R. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1155-1158.
26. Zarate C.A, Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.
27. Maes M., Verkerk R., Vandoolaeghe E., Lin A., Scharpé S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 1998, 97:302-308.
28. Bonanno G., Giambelli R., Raiteri L., Tiraboschi E., Zappettini S., Musazzi L., et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 2005, 25:3270-3279.
29. Tokarski K., Bobula B., Wabno J., Hess G. Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex. Neuroscience 2008, 153:789-795.
30. Musazzi L., Milanese M., Farisello P., Zappettini S., Tardito D., Barbiero V.S., et al. Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants. PLOS ONE 2010, 5:e8566.
31. Brown D.R., Kretzschmar H.A. The glio-toxic mechanism of alpha-aminoadipic acid on cultured astrocytes. J Neurocytol 1998, 27:109-118.
32. Olney J.W., de Gubareff T., Collins J.F. Stereospecificity of the gliotoxic and anti-neurotoxic actions of alpha-aminoadipate. Neurosci Lett 1980, 19:277-282.
33. Huck S., Grass F., Hatten M.E. Gliotoxic effects of alpha-aminoadipic acid on monolayer cultures of dissociated postnatal mouse cerebellum. Neuroscience 1984, 12:783-791.
34. Huck S., Grass F., Hörtnagl H. The glutamate analogue alpha-aminoadipic acid is taken up by astrocytes before exerting its gliotoxic effect in vitro. J Neurosci 1984, 4:2650-2657.
35. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008, 7:426-437.
36. Skolnick P., Layer R.T., Popik P., Nowak G., Paul I.A., Trullas R. Adaptation of N-methyl-d-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996, 29:23-26.
37. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999, 375:31-40.
38. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
39. Kendell S.F., Krystal J.H., Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin Ther Targets 2005, 9:153-168.
40. Ostroff R., Gonzales M., Sanacora G. Antidepressant effect of ketamine during ECT. Am J Psychiatry 2005, 162:1385-1386.
41. Chung C. New perspectives on glutamate receptor antagonists as antidepressants. Arch Pharm Res 2012, 35:573-577.
42. Pochwat B., Pałucha-Poniewiera A., Szewczyk B., Pilc A., Nowak G. NMDA antagonists under investigation for the treatment of major depressive disorder. Expert Opin Investig Drugs 2014, 12:1-12.
43. Pin J.P., Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995, 34:1-26.
44. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997, 37:205-237.
45. Schoepp D.D., Jane D.E., Monn J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999, 38:1431-1476.
46. Busse C.S., Brodkin J., Tattersall D., Anderson J.J., Warren N., Tehrani L., et al. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 2004, 29:1971-1979.
47. Pałucha A., Brański P., Szewczyk B., Wierońska J.M., Kłak K., Pilc A. Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav 2005, 81:901-906.
48. Pałucha-Poniewiera A., Wierońska J.M., Brański P., Burnat G., Chruścicka B., Pilc A. Is the mGlu5 receptor a possible target for new antidepressant drugs. Pharmacol Rep 2013, 65:1506-1511.
49. Pałucha-Poniewiera A., Brański P., Wierońska J.M., Stachowicz K., Sławińska A., Pilc A. The antidepressant-like action of mGlu5 receptor antagonist, MTEP, in the tail suspension test in mice is serotonin dependent. Psychopharmacology (Berl) 2014, 231:97-107.
50. Stachowicz K., Gołembiowska K., Sowa M., Nowak G., Chojnacka-Wójcik E., Pilc A. Anxiolytic-like action of MTEP expressed in the conflict drinking Vogel test in rats is serotonin dependent. Neuropharmacology 2007, 53:741-748.
51. Domin H., Zieba B., Gołembiowska K., Kowalska M., Dziubina A., Śmiałowska M. Neuroprotective potential of mGluR5 antagonist MTEP: effects on kainate-induced excitotoxicity in the rat hippocampus. Pharmacol Rep 2010, 62:1051-1061.
52. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1986, Academic Press, San Diego. 2nd ed.
53. Nowak G., Szewczyk B., Wieronska J.M., Branski P., Palucha A., Pilc A., et al. Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull 2003, 61:159-164.
54. Maćkowiak M., Bator E., Latusz J., Mordalska P., Wedzony K. Prenatal MAM administration affects histone H3 methylation in postnatal life in the rat medial prefrontal cortex. Eur Neuropsychopharmacol 2014, 24:271-289.
55. Sterio D.C. The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc 1984, 134:127-136.
56. Gundersen H.J., Jensen E.B., Kiêu K., Nielsen J. The efficiency of systematic sampling in stereology - reconsidered. J Microsc 1999, 193:199-211.
57. John C.S., Smith K.L., Van't Veer A., Gompf H.S., Carlezon W.A., Cohen B.M., et al. Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia. Neuropsychopharmacology 2012, 37:2467-2475.
58. Bechtholt-Gompf A.J., Walther H.V., Adams M.A., Carlezon W.A., Ongür D., Cohen B.M. Blockade of astrocytic glutamate uptake in rats induces signs of anhedonia and impaired spatial memory. Neuropsychopharmacology 2010, 35:2049-2059.
59. Lee Y., Gaskins D., Anand A., Shekhar A. Glia mechanisms in mood regulation: a novel model of mood disorders. Psychopharmacology (Berl) 2007, 191:55-65.
60. Zink M., Vollmayr B., Gebicke-Haerter P.J., Henn F.A. Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. Neuropharmacology 2010, 58:465-473.
61. Chaudhry F.A., Lehre K.P., van Lookeren Campagne M., Ottersen O.P., Danbolt N.C., Storm-Mathisen J. Glutamate transporters in glial plasma membranes: highly differentiated localizations revealed by quantitative ultrastructural immunocytochemistry. Neuron 1995, 15:711-720.
62. Sun J.D., Liu Y., Yuan Y.H., Li J., Chen N.H. Gap junction dysfunction in the prefrontal cortex induces depressive-like behaviors in rats. Neuropsychopharmacology 2012, 37:1305-1320.
63. Olney J.W., Ho O.L., Rhee V. Cytotoxic effects of acidic and sulphur containing amino acids on the infant mouse central nervous system. Exp Brain Res 1971, 14:61-76.
64. Bruni J.E., Vriend J. Effect of d,l-alpha-aminoadipate on the mediobasal hypothalamus and endocrine function in the rat. Acta Neuropathol 1984, 64:129-138.
65. Nishimura R.N., Santos D., Fu S.T., Dwyer B.E. Induction of cell death by l-alpha-aminoadipic acid exposure in cultured rat astrocytes: relationship to protein synthesis. Neurotoxicology 2000, 21:313-320.
66. Pannicke T., Stabel J., Heinemann U., Reichelt W. alpha-Aminoadipic acid blocks the Na(+)-dependent glutamate transport into acutely isolated Müller glial cells from guinea pig retina. Pflugers Arch 1994, 429:140-142.
67. Khurgel M., Koo A.C., Ivy G.O. Selective ablation of astrocytes by intracerebral injections of alpha-aminoadipate. Glia 1996, 16:351-358.
68. Takada M., Hattori T. Fine structural changes in the rat brain after local injections of gliotoxin, alpha-aminoadipic acid. Histol Histopathol 1986, 1:271-275.
69. Chang F.W., Wang S.D., Lu K.T., Lee E.H. Differential interactive effects of gliotoxin and MPTP in the substantia nigra and the locus coeruleus in BALB/c mice. Brain Res Bull 1993, 31:253-266.
70. Saffran B.N., Crutcher K.A. Putative gliotoxin, alpha-aminoadipic acid, fails to kill hippocampal astrocytes in vivo. Neurosci Lett 1987, 81:215-220.
71. Kroczka B., Branski P., Palucha A., Pilc A., Nowak G. Antidepressant-like properties of zinc in rodent forced swim test. Brain Res Bull 2001, 55:297-300.
72. Sofroniew M.V., Vinters H.V. Astrocytes: biology and pathology. Acta Neuropathol 2010, 119:7-35.
73. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978, 47:379-391.
74. Rogóz Z., Budziszewska B., Kubera M., Basta-Kaim A., Jaworska-Feil L., Skuza G., et al. Effect of combined treatment with imipramine and metyrapone on the immobility time, the activity of hypothalamo-pituitary-adrenocortical axis and immunological parameters in the forced swimming test in the rat. J Physiol Pharmacol 2005, 56:49-61.
75. Papp M., Wieronska J. Antidepressant-like activity of amisulpride in two animal models of depression. J Psychopharmacol 2000, 14:46-52.
76. Li L.F., Yang J., Ma S.P., Qu R. Magnolol treatment reversed the glial pathology in an unpredictable chronic mild stress-induced rat model of depression. Eur J Pharmacol 2013, 711:42-49.
77. Liu Q., Li B., Zhu H.Y., Wang Y.Q., Yu J., Wu G.C. Clomipramine treatment reversed the glial pathology in a chronic unpredictable stress-induced rat model of depression. Eur Neuropsychopharmacol 2009, 19:796-805.
78. Czéh B., Simon M., Schmelting B., Hiemke C., Fuchs E. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology 2006, 31:1616-1626.
79. Czéh B., Müller-Keuker J.I., Rygula R., Abumaria N., Hiemke C., Domenici E., et al. Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment. Neuropsychopharmacology 2007, 32:1490-1503.
80. Czéh B., Di Benedetto B. Antidepressants act directly on astrocytes: evidences and functional consequences. Eur Neuropsychopharmacol 2013, 23:171-185.
81. Anderson J.J., Rao S.P., Rowe B., Giracello D.R., Holtz G., Chapman D.F., et al. [3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J Pharmacol Exp Ther 2002, 303:1044-1051.
82. Cosford N.D., Roppe J., Tehrani L., Schweiger E.J., Seiders T.J., Chaudary A., et al. [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett 2003, 13:351-354.
83. Hughes Z.A., Neal S.J., Smith D.L., Sukoff Rizzo S.J., Pulicicchio C.M., Lotarski S., et al. Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression. Neuropharmacology 2013, 66:202-214.
84. Tatarczyńska E., Klodzińska A., Chojnacka-Wójcik E., Palucha A., Gasparini F., Kuhn R., et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol 2001, 132:1423-1430.
85. Li X., Need A.B., Baez M., Witkin J.M. Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther 2006, 319:254-259.
86. Belozertseva I.V., Kos T., Popik P., Danysz W., Bespalov A.Y. Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol 2007, 17:172-179.
87. Slattery D.A., Hudson A.L., Nutt D.J. Invited review: the evolution of antidepressant mechanisms. Fundam Clin Pharmacol 2004, 18:1-21.
88. Duman R.S. Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections. Depress Anxiety 2014, 31:291-296.
89. Lang U.E., Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem 2013, 31:761-777.
90. Zarate C.A, Mathews D.C., Furey M.L. Human biomarkers of rapid antidepressant effects. Biol Psychiatry 2013, 73:1142-1155.
91. Szewczyk B., Pałucha-Poniewiera A., Poleszak E., Pilc A., Nowak G. Investigational NMDA receptor modulators for depression. Expert Opin Investig Drugs 2012, 21:91-102.
92. Tu J.C., Xiao B., Naisbitt S., Yuan J.P., Petralia R.S., Brakeman P., et al. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 1999, 23:583-592.
93. Xiao B., Tu J.C., Petralia R.S., Yuan J.P., Doan A., Breder C.D., et al. Homer regulates the association of group 1 metabotropic glutamate receptors with multivalent complexes of homer-related, synaptic proteins. Neuron 1998, 21:707-716.
94. Jin D.Z., Guo M.L., Xue B., Mao L.M., Wang J.Q. Differential regulation of CaMKIIα interactions with mGluR5 and NMDA receptors by Ca(2+) in neurons. J Neurochem 2013, 127:620-631.
95. Doherty A.J., Palmer M.J., Bortolotto Z.A., Hargreaves A., Kingston A.E., Ornstein P.L., et al. A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. Br J Pharmacol 2000, 131:239-244.
96. Dzamba D., Honsa P., Anderova M. NMDA receptors in glial cells: pending questions. Curr Neuropharmacol 2013, 11:250-262.
97. Balázs R., Miller S., Romano C., de Vries A., Chun Y., Cotman C.W. Metabotropic glutamate receptor mGluR5 in astrocytes: pharmacological properties and agonist regulation. J Neurochem 1997, 69:151-163.
98. Zhang Y., Rodriguez A.L., Conn P.J. Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J Pharmacol Exp Ther 2005, 315:1212-1219.
99. Paquet M., Ribeiro F.M., Guadagno J., Esseltine J.L., Ferguson S.S., Cregan S.P. Role of metabotropic glutamate receptor 5 signaling and homer in oxygen glucose deprivation-mediated astrocyte apoptosis. Mol Brain 2013, 6:9.
100. Mishra A., Mishra R., Gottschalk S., Pal R., Sim N., Engelmann J., et al. Microscopic visualization of metabotropic glutamate receptors on the surface of living cells using bifunctional magnetic resonance imaging probes. ACS Chem Neurosci 2014, 5:128-137.
101. 2+ oscillations in striatum. PLOS ONE 2014, 9:e85351.
102. Lea P.M., Custer S.J., Vicini S., Faden A.I. Neuronal and glial mGluR5 modulation prevents stretch-induced enhancement of NMDA receptor current. Pharmacol Biochem Behav 2002, 73:287-298.
103. D'Ascenzo M., Fellin T., Terunuma M., Revilla-Sanchez R., Meaney D.F., Auberson Y.P., et al. mGluR5 stimulates gliotransmission in the nucleus accumbens. Proc Natl Acad Sci USA 2007, 104:1995-2000.
104. Cleva R.M., Olive M.F. Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders. Molecules 2011, 16:2097-2106.
105. Domin H., Kajta M., Smiałowska M. Neuroprotective effects of MTEP, a selective mGluR5 antagonists and neuropeptide Y on the kainate-induced toxicity in primary neuronal cultures. Pharmacol Rep 2006, 58:846-858.
106. Abushik P.A., Niittykoski M., Giniatullina R., Shakirzyanova A., Bart G., Fayuk D., et al. The role of NMDA and mGluR5 receptors in calcium mobilization and neurotoxicity of homocysteine in trigeminal and cortical neurons and glial cells. J Neurochem 2014, 129:264-274.
107. Takano K., Yamasaki H., Kawabe K., Moriyama M., Nakamura Y. Imipramine induces brain-derived neurotrophic factor mRNA expression in cultured astrocytes. J Pharmacol Sci 2012, 120:176-186.
108. Schmidt H.D., Banasr M., Duman R.S. Future antidepressant targets: neurotrophic factors and related signaling cascades. Drug Discov Today Ther Strateg 2008, 5:151-156.
109. Elsayed M., Banasr M., Duric V., Fournier N.M., Licznerski P., Duman R.S. Antidepressant effects of fibroblast growth factor-2 in behavioral and cellular models of depression. Biol Psychiatry 2012, 72:258-265.
110. Di Benedetto B., Radecke J., Schmidt M.V., Rupprecht R. Acute antidepressant treatment differently modulates ERK/MAPK activation in neurons and astrocytes of the adult mouse prefrontal cortex. Neuroscience 2013, 232:161-168.
111. Fatemi S.H., Folsom T.D., Reutiman T.J., Pandian T., Braun N.N., Haug K. Chronic psychotropic drug treatment causes differential expression of connexin 43 and GFAP in frontal cortex of rats. Schizophr Res 2008, 104:127-134.
112. Mercier G., Lennon A.M., Renouf B., Dessouroux A., Ramaugé M., Courtin F., et al. MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes. J Mol Neurosci 2004, 24:207-216.
113. Chung C. New perspectives on glutamate receptor antagonists as antidepressants. Arch Pharm Res 2012, 35:573-577.
114. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008, 63:349-352.
115. Zarate C.A, Mathews D., Ibrahim L., Chaves J.F., Marquardt C., Ukoh I., et al. A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression. Biol Psychiatry 2013, 74:257-264.